RedHill Biopharma Ltd. (RDHL) reported preliminary results of a preclinical study showing strong inhibition by opaganib of COVID-19 Delta variant replication while maintaining cell viability at relevant concentrations. Opaganib is a small molecule investigational oral pill in development for the treatment of COVID-19. The company said this data from a human bronchial epithelial cells model adds to prior data showing potent inhibition of all COVID-19 variants tested to date.
RedHill Biopharma said Opaganib's global phase 2/3 study in hospitalized patients with COVID-19 has completed its treatment and follow up phase, and study top-line results are upcoming.
Shares of RedHill Biopharma were up 15% in pre-market trade on Thursday.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.